Kornimate/medical-research-clean huggingface dataset:
development of a questionnaire based on patients' messages on an internet forum for flare detection in ibd

Conditions: Inflammatory Bowel Diseases

Summary: crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease (ibd) are chronic disabling conditions characterized by flares followed by periods of remission. however, ibd patients are seen every 3 to 6 months in the outpatient clinic, and the occurrence of a flare between two outpatient visits is not captured. in the current state of knowledge, there is no validated patient-reported outcome (pro) tool to measure the phenomenon of flare in ibd. this study aimed to use an innovative methodology to collect messages posted by patients in an internet forum for developing and validating a pro measuring flare in ibd. the design involves 1) engineering sciences for scraping extraction of messages posted in an internet forum and for identification of messages related to flare, 2) qualitative methods for thematic content analyze of the messages posted, for candidate items generation, for items selection (delphi process) and for items adjustment ("think aloud" interviews), 3) quantitative methods for psychometric validation of the pro.


Eligibility criteria:
inclusion criteria: * every patient consulting the gastroenterology unit of nancy university hospital with a confirmed ibd diagnosis, regardless of the patient's state or treatment will be considered for inclusion exclusion criteria: * patients with a diagnosis \< 3 months. * protected persons (minors, adults under guardianship, pregnant or breastfeeding women, people living in a public health or social institution, patients in an emergency situation, incarcerated individuals)

Keywords: flare inflammatory bowel diseases questionnaire internet mixed methods
clinico-biological characterization and survival of patients with adult t-cell leukemia / lymphoma (atl) and patients chronically infected with the htlv-1 virus (htlv-obs)

Conditions: Lymphoproliferation Induced by HTLV-1; HTLV-1 Adult T-cell Lymphoma / Leukemia; HTLV-1 Infection

Summary: the purpose of this study is to evaluate the outcome (survival) of adult t-cell leukemia / lymphoma (atl) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of htlv-1 chronically infected patients with / without extra-haematological disorders (cohort 2).


Eligibility criteria:
inclusion criteria: * 18 years old or older * htlv-1 infected * t lymphoproliferation induced by htlv-1 (cohort 1) * without t lymphoproliferation induced by htlv-1 (cohort 2) * informed and accepted the collection of data exclusion criteria - patients refusal of participation

Keywords: human t-lymphotropic virus 1 lymphoma leukemia
a long-term, safety study with a flexible dose range of kw-6002 in patients with motor response complications on levodopa/carbidopa therapy

Conditions: Parkinson's Disease

Summary: the primary objective of this study was to establish the long-term tolerability and safety of istradefylline treatment in subjects with parkinson's disease treated with levodopa/carbidopa. in addition, treatment response and maintenance of response were assessed.


Eligibility criteria:
inclusion criteria: eligible subjects were: * male or female * at least 30 years of age * had completed participation in a prior double-blind istradefylline trial * met united kingdom's parkinson's disease society (ukpds) brain bank criteria (step 1 and step 2) for parkinson's disease and the severity of the parkinson's disease was defined as stages 2-4 on the modified hoehn and yahr scale while in the off state * had been treated with levodopa for at least 1 year * had been on a stable parkinson's disease regimen within normal therapeutic ranges including levodopa for at least 4 weeks before baseline * were currently taking at least 4 doses of levodopa per day (3 doses per day if at least 2 doses contained slow-release formulation) * had predictable end-of-dose wearing-off exclusion criteria: * none

Keywords: long-term tolerability and safety istradefylline treatment levodopa/carbidopa
clinical outcomes of pimsra treating for hypertrophic obstructive cardiomyopathy: a large-sample study

Conditions: Hypertrophic Obstructive Cardiomyopathy (HOCM)

Summary: the hypertrophic cardiomyopathy center of xijing hospital pioneered percutaneous intramyocardial septal radiofrequency ablation (pimsra) as an innovative treatment for hypertrophic obstructive cardiomyopathy (hocm) to relieve left ventricular outflow tract obstruction. clinical studies have confirmed pimsra's efficacy, safety and reliability, establishing it as a novel alternative for septal reduction therapy. as a novel interventional approach, comprehensive evaluation of its safety and therapeutic effectiveness is warranted. therefore, this retrospective study aims to: * investigate postoperative clinical outcomes and their influencing factors in hocm patients undergoing pimsra; * analyze morphological and hemodynamic changes including: septal thickness, left ventricular outflow tract gradient, mid-ventricular pressure gradient and left ventricular flow field dynamics; * examine correlations between clinical/procedural parameters and clinical symptoms, quality of life and cardiac reverse remodeling indicators. this study will provide high-quality evidence to support the clinical application of this novel procedure.


Eligibility criteria:
inclusion criteria: * all hocm patients who underwent pimsra treatment, including those with left ventricular outflow tract and middle ventricular obstruction; * age from 18 to 90 years old. exclusion criteria: * patients lost to follow-up whose follow-up period did not reach 6 months; * incomplete clinical data affected statistical analysis.

Keywords: cardiomyopathy, hypertrophic treatment outcome safety efficacy percutaneous intramyocardial septal radiofrequency ablation
physical fitness, cardiovascular and brain health

Conditions: Hypertension

Summary: the goal of this study is to determine if aerobic exercise or progressive muscle relaxation is associated with changes in cardiovascular health, brain function, and cognition.

cognition is the most important determinant of health status, quality of life and functional ability in older age. therefore, early interventions that preserve and enhance cognitive function are crucial for ensuring successful aging. the most common treatable risk factor for late-life cognitive impairment is midlife hypertension (htn). one highly promising intervention strategy is aerobic exercise as it has been associated cognitive benefits in non-demented older adults. however, it is still unclear whether this benefit is due simply to prevention of other risk factors (e.g., reductions in blood pressure) or if exercise can reverse the negative effects of htn on the brain. the goals of the current study are to employ sensitive measures of neuroimaging and cognition in order to 1).compare cerebral health in endurance trained versus sedentary middle aged adults with normal or borderline to stage 1 hypertension, 2). measure the effects of exercise training in previously sedentary middle aged adults adults with normal or borderline to stage 1 hypertension, and 3). examine if exercise-related differences and changes in neural integrity and cognition are mediated by systemic vascular health.

Eligibility criteria:
inclusion criteria: * sedentary adults participants will be classified as sedentary if they have not engaged in regular physical exercise for at least one year prior to study enrollment. * ages 45-65 * normal blood pressure or borderline or stage 1 hypertension borderline hypertension will be defined as systolic blood pressure between 120-139 mmhg and/or diastolic blood pressure between 80-89 mmhg. stage 1 hypertension will be defined as systolic blood pressure between 140-159 mmhg and/or diastolic blood pressure between 90-99 mmhg. exclusion criteria: * signs or symptoms of chronic heart disease * smoking (current or within the past 6 months) * peripheral artery disease (ankle-brachial index\<0.9) * diabetes (fasting blood glucose\>126 mg/l) * orthopedic problems that would prohibit participants from participating in exercise. * axis i psychiatric disorder * magnetic resonance contraindications * baseline intellectual quotient \< 70 * below chance performance on the practice items of the cognitive tasks * evidence of large vessel stroke on magnetic resonance imaging

Keywords: hypertension aerobic exercise relaxation functional magnetic resonance imaging (fmri) magnetic resonance spectroscopy (mrs) brain health
study of safety,efficacy and pharmacokinetics of ct-1530 in patients with relapsed or refractory b cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and waldenstrom's macroglobulinemia

Conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Waldenstrom's Macroglobulinemia; Mantle Zone Lymphoma Refractory/Recurrent; Follicle Centre Lymphoma Diffuse; Diffuse Large B Cell Lymphoma

Summary: this is a phase i study of btk inhibitor ct-1530 in patients with relapsed or refractory b cell non-hodgkin lymphoma (b-nhl), chronic lymphocytic leukemia (cll) or waldenstrom's macroglobulinemia (wm). the purpose of the study is to determine the mtd/rp2d of ct-1530, and evaluate its safety and tolerability as monotherapy in subjects with relapsed or refractory b cell non-hodgkin lymphoma (b-nhl), chronic lymphocytic leukemia (cll) or waldenstrom's macroglobulinemia (wm).


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of b cell non-hodgkin lymphoma(according to world health organization \[who\] classification)including chronic lymphocytic leukemia/small cell lymphocytic leukemia (international workshop),or waldenstrom's macroglobulinemia(second international workshop). * have failed ≥1 previous treatment for b-nhl/cll/wm, and have relapsed or refractory disease following last prior treatment. * eastern cooperative oncology group performance status of ≤ 1 and a life expectancy of at least 3 months. * measurable disease as per recist v1.1 * availability of tumor sample * adequate hematologic function, as defined by neutrophils ≥ 1.0 x 10\^9/l and platelets ≥ 50 x 10\^9/l; patients with neutrophils \< 1.0 x 10\^9/l due to marrow infiltration are allowed to receive growth factors to bring pre-treatment neutrophils to ≥ 1.0 x 10\^9/l. * adequate renal function, as defined by creatinine clearance of ≥ 50 ml/min (as estimated by the cockcroft-gault equation or as measured by nuclear medicine scan or 24 hour urine collection). * adequate liver function, as defined by ast and alt ≤ 3 x uln, and bilirubin ≤ 1.5 x uln (unless documented gilbert's syndrome). exclusion criteria: * prior allogeneic bone marrow transplant * autologous stem cell transplant within 3 months of screening * active central nervous system involvement * subjects with autoimmune hemolytic anemia or immune thrombocytopenia * prior treatment with a btk inhibitor * active uncontrolled infection * history of malabsorption * uncontrolled illness, i.e cardiac, endocrine, respiratory, etc. * history of myocardial infarction, acute coronary syndromes, coronary angioplasty and/or stenting with in the previous 6 months * history of another currently active cancer * history of major surgery within 4 weeks or minor surgery within 1 week * other medical or psychiatric illness or organ dysfunction * hiv positive * positive for hepatitis b surface antigen or hepatitis c-virus other protocol-defined inclusion/exclusion criteria may apply
a phase iv safety and efficacy study of vi-0521 in adolescents with obesity

Conditions: Adolescent Obesity; Obesity in Adolescence; Adolescent Overweight

Summary: this study is being conducted to assess weight loss efficacy, as determined by changes in body mass index (bmi), and safety of vi-0521 (qsymia®) or placebo, taken for 56 weeks accompanied by a lifestyle modification program in obese adolescents age 12-16 years.


Eligibility criteria:
inclusion criteria: * aged ≥ 12 years and \< 17 years; * bmi ≥ the 95th percentile, with documented history of failure to lose sufficient weight or failure to maintain weight loss in a lifestyle modification program; * if female, must be using adequate contraception, defined as double barrier methods, stable hormonal contraception plus single barrier method, tubal ligation, or abstinence. exclusion criteria: * type 1 diabetes; * congenital heart disease; clinically significant ecg abnormality; * clinically significant physical exam, vital signs, or laboratory abnormality; clinically significant hepatic or renal disease; * estimated glomerular filtration rate (gfr; schwartz formula) \< 60 ml/minute; * clinically significant thyroid dysfunction as evidenced by signs, symptoms, or thyroid stimulating hormone (tsh) \> 1.5 x upper limit of normal; * obesity of known genetic or endocrine origin; * history of bipolar disorder or psychosis, depression of moderate or greater severity, or presence or history of suicidal behavior or active suicidal ideation; * recent weight instability, or prior bariatric surgery; * history of glaucoma or increased intraocular pressure; * current smoker or smoking cessation within 3 months of screening; * currently taking or plan on taking any of following medications during the study: * anticonvulsants used for treatment of seizure disorder, including barbiturates, benzodiazepines, gamma-aminobutyric acid (gaba) analogues, hydantoins, phenyltriazines, succinimides, and other agents (valproic acid and its derivatives, carbamazepine and its derivatives, zonisamide, and felbamate); * tricyclic antidepressants, monoamine oxidase inhibitors (maois), lithium, levodopa, and dopamine receptor agonists; * carbonic anhydrase inhibitors; * insulin, sulfonylureas (sfus), glucagon-like peptide -1 (glp-1) agonists, sodium glucose transporter-1 (sglt-1), and sglt-2 inhibitors; * chronic systemic steroids (i.e. glucocorticoids, anabolic steroids) other than oral contraceptives; * treatment for hyperactivity disorder; or * over the counter, prescription medications, herbal agents and dietary supplements used with the intention to lose body weight.

Keywords: weight loss obesity weight control
ischemic postconditioning in stemi patients treated with primary pci

Conditions: ST Segment Elevation Myocardial Infarction

Summary: in a prospective, randomized clinical trial the ipost2 trial will determine whether ischemic postconditioning reduces reperfusion injury and this will translate into improved clinical outcome of heart failure and death for stemi patients who present with timi0-1 undergoing primary pci

myocardial reperfusion with the use primary percutaneous coronary intervention (pci) is effective, but restoration of blood flow may itself jeopardize the myocardium, a phenomenon known as reperfusion injury. in ischemic postconditioning (ipost), repetitive interruptions of blood flow to the injured region applied after initial reperfusion, has been shown favorable with different modalities such as biomarkers, echocardiography and cardiac magnetic resonance. however, the largest trial to date (danami3-ipost) failed to show clinical favor of ipost when compared to conventional pci. importantly, however, in danami3-ipost thrombectomy was allowed and this might have impaired postconditioning, since thrombectomy itself creates reperfusion and thus reperfusion damage. analysis of the fraction of danami3-ipost patients not undergoing thrombectomy showed a remarkable 45% reduction in death and heart failure in favor of postconditioning. ipost2 will investigate in a randomized, prospective and adequately powered trial the effect of ipost without thrombectomy compared to conventional pci on the development of heart failure and death in stemi patients.

Eligibility criteria:
inclusion criteria: * age ≥18 years * acute onset of chest pain with \< 12 hours duration * stemi as characterized by 2 mm st elevation in 2 or more v1 through v4 leads or presumed new left bundle branch block with minimum of 1 mm concordant st elevation or 1 mv st-segment elevation in the limb lead (ii, iii and avf, i, avl) and v4-v6 or st depression in 2 or more v1 through v4 leads indicating posterior ami. * timi flow 0-1 in infarct related artery exclusion criteria: * potential pregnancy * refusal to participate * ohca without subsequent consciousness despite rosc * thrombectomy considered unavoidable

Keywords: primary pci ischemic postconditioning clinical outcome
anasa (patients' satisfaction with pulmonary diseases' treatment)

Conditions: Asthma; Chronic Obstructive Pulmonary Disease

Summary: the aim of the study is to compare patients' satisfaction from the use of three different inhalation devices by using the fsi-10 questionnaire

patients are requested to reply to fsi-10 questionnaire regarding their satisfaction from inhalation devices. patients are on 3 different asthma inhalation devices with combination treatment (turbuhaler, diskus, elpenhaler)

Eligibility criteria:
inclusion criteria: * patients \> 18 years old, both genders who are on their inhalation treatment at least two months before study enrollment, * who are able to be compliant to study procedures exclusion criteria: * patients \< 18 years old, * patients who are on their inhalation treatment less than two months before study enrollment * patients who are not able to be compliant to study procedures

Keywords: copd
cannabinoids effects on the pain modulation system

Conditions: Neuropathic Pain

Summary: effective treatment of acute pain, chronic and persistent is the most important concern in the world today. although a variety of pain medications including anti-inflammatory painkillers and opiouids, patients continue to suffer from pain constantly. for over a century ,international committees studied the issue of cannabis, and almost uniformly recommended the use of cannabis for various medical applications ,especially those that include pain treatment. despite the widespread use of thc in clinical practice, there are few studies on the efficacy of thc in a double-blind, randomized trial. in addition, few studies examined the effect of thc on the experience pain in healthy subjects and most of them did not find an effect on pain experimental induced by capsain. so checking other models of pain such as thermal pain and mechanical pain in addition to checking the influence on the regulation of pain will contribute to understanding the mechanism of action of thc. understanding the mechanism of action of thc in relieving pain will lead to predicting who will benefit from this treatment and direct patients for selection of appropriate medication according to the damaged mechanism.


Eligibility criteria:
inclusion criteria: a. men aged 25-65. b. were not treated with formulation contains cannabis c. can sign an informed consent form. d. patients have a medical history that supports severe neuropathic pain over three months and do not respond to other painkillers or suffer from side effects resulting from the use them e. at least moderate pain (more than 40 on a scale of 0-100 visual analogue scale). f. did not receive epidural injection or invasive treatment in the last month before the entry to study . g. not drinking alcohol or consuming high concentrations of opioid and benzodiazifinim over 24 hours before the experiment (equivalent to 40 mg morphine). exclusion criteria: a. patients that found with serious level of anxiety in patient health questionnaire (phq-9) . (these patients will be recommended by a doctor appointment with a psychiatrist). b.patients with psychiatric problems or a family history of psychiatric disorders. c.patients with known cardiovascular problems d.patients with neurological problems from a central source e.patients taking blood pressure medication f.patients who are unable to understand and follow the instruction of the study. g.diffuse pain syndromes from uncertain origin (like fibromyalgia) h.alcoholism or chronic use of drugs. i.malignant
assessment of the efficacy of vitamins a and d and γ-oryzanol-fortified canola oil in adults with type 2 diabetes

Conditions: Diabetes

Summary: the aim of this study is to evaluate the efficacy of daily intake of fortified canola oil with vitamins a and d and γ-oryzanol on anthropometric, inflammatory, immunity, appetite and metabolic indicators of adults with type 2 diabetes compared to canola and sunflower oil without γoryzanol.

ninety confirmed type 2 diabetes patients aged 20-65 years old will be selected. participants who change their usual medicine intake or make any changes in their diet and lifestyle that could alter the effectiveness of the intervention as well as those who do not use the fortified oil for three consecutive days or do not use the fortified oil for more than ten days throughout the intervention will be excluded. subjects will be assigned randomly to one of the three intervention groups: 1.fortified canola oil with vitamins a and d and γ-oryzanol , 2. fortified canola oil with vitamins a and d, 3. fortified sunflower oil with vitamins a and d. each participant will consume 30 g of oil every day for 2 months. at the first and last visits, dietary and laboratory assessments will be performed for all subjects. the primary outcomes are the improvement of anthropometric, inflammatory, immunity, appetite, glycemic, and lipidemic markers of adults with type 2 diabetes.

Eligibility criteria:
inclusion criteria: 1. type 2 diabetic patients with fasting blood sugar above 100 mg/dl or hemoglobin a1c above 6% in the last test 2. age between 20 to 65 years 3. no use of insulin exclusion criteria: 1. changing usual medicine intake or making any changes in diet and lifestyle that could alter the effectiveness of the intervention 2. not using the fortified oil for three consecutive days or not using the fortified oil for more than ten days throughout the intervention period

Keywords: vitamin a vitamin d γ-oryzanol fortified oil
hypertensive pregnant women monitored by teletransmitted self-measurements of blood pressure

Conditions: Hypertension in Pregnancy

Summary: the occurrence of arterial hypertension (ah) during pregnancy is a major cause of fetal, neonatal and maternal morbidity and mortality in western countries. it is estimated that about 10% of pregnancies are complicated by ah (80 000 women / year in france). it is therefore essential to diagnose ah with certainty in order to set-up appropriate care and follow its evolution.

the objective of this study is to show the faisability of self-measurement with teletransmission for long-term follow-up of hypertensive pregnant women (at high risk of preeclampsia) by avoiding repeated, prolonged visits or hospitalizations and to optimize the intervention of health professionals by providing them with reliable data. a multicenter, controlled study will be conducted in women presenting with mild to moderate hypertension without preeclampsia followed throughout their pregnancy by either self-measurement with teletransmission.

Eligibility criteria:
inclusion criteria: * pregnant women with confirmed mild to moderate ah untreated and / or under antihypertensive treatment (for gestational or chronic hypertension) * women without preeclampsia requiring enhanced ah surveillance * patient affiliated to a social security system * patient giving consent to participate in the study. * age\> 18 years exclusion criteria: * arm circumference greater than 42 cm unsuitable for self-measurement, * women in atrial fibrillation, or frequently in arrhythmia, with secondary hypertension or severe hypertension or with cardiovascular complication. * women having preeclampsia. * women having an ah by "white coat effect". * women having a move or maternity change planned during pregnancy. * majors protected under tutorship or curatorship, or under the protection of justice.

Keywords: pregnancy hypertension telemonitoring